Yıldırım, H. Ç. Et Al. 2022. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.. Breast (Edinburgh, Scotland) , vol.66 , 85-88.

Yıldırım, H. Ç., Mutlu, E., Chalabiyev, E., Özen, M., Keskinkılıç, M., Ön, S., ... Çelebi, A.(2022). Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.. Breast (Edinburgh, Scotland) , vol.66, 85-88.

Yıldırım, Hasan Et Al. "Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.," Breast (Edinburgh, Scotland) , vol.66, 85-88, 2022

Yıldırım, Hasan Ç. Et Al. "Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.." Breast (Edinburgh, Scotland) , vol.66, pp.85-88, 2022

Yıldırım, H. Ç. Et Al. (2022) . "Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.." Breast (Edinburgh, Scotland) , vol.66, pp.85-88.

@article{article, author={Hasan Çağrı Yıldırım Et Al. }, title={Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.}, journal={Breast (Edinburgh, Scotland)}, year=2022, pages={85-88} }